作者：郭晶，何萍，王正雨

单位：

223002江苏省淮安市第二人民医院药剂科 通信作者：郭晶，E-mail：2306583127@qq.com

单位（英文）：

Department of Pharmacy, Huai'an Second People's Hospital, Huai'an 223002, China Corresponding author: GUO Jing, E-mail: 2306583127@qq.com

关键词：

肺肿瘤; 肺癌; 老年人; 安罗替尼; 危险因素; 治疗结果;

关键词（英文）：

Lung neoplasms; Lung cancer; Aged; Arotinib; Risk factors; Treatment outcome

中图分类号：

DOI：

10.12114/j.issn.1008-5971.2022.00.114

基金项目：

摘要：

目的 分析安罗替尼治疗老年肺癌患者的疗效及患者预后的危险因素。方法 回顾性选取2018-11-01至2020-06-30淮安市第二人民医院收治的老年肺癌患者73例为研究对象。所有患者采用盐酸安罗替尼胶囊进行治疗，共治疗21 d。收集患者一般资料、临床疗效[计算客观缓解率（ORR）和疾病控制率（DCR）]、预后指标[无进展生存期（PFS）、总生存期（OS）]、安全性指标（治疗期间毒副作用发生情况）。采用多因素Logistic回归分析探讨老年肺癌患者预后（PFS、OS）的影响因素。结果 73例患者的ORR为8.2%(6/73),DCR为56.2%(41/73)。病理分期为Ⅲ期的患者ORR、DCR大于病理分期为Ⅳ期的患者（P<0.05）;ECOG评分≤1分患者DCR大于ECOG评分≥2分患者（P<0.05）。73例患者的平均PFS为（5.2±2.0）个月，平均OS为（11.2±3.6）个月。多因素Logistic回归分析结果显示，年龄[OR=0.270,95%CI(0.082,0.882)]、三线治疗[OR=0.127,95%CI(0.023,0.704)]是老年肺癌患者PFS的影响因素（P<0.05）。73例患者中，发生乏力27例（37.0%）、胃肠道反应24例（32.9%）、出血8例（11.0%）、新发高血压6例（8.2%）、蛋白尿5例（6.8%），给予降压药、抑酸护胃药、促胃动力药及补气血类中药等相关处理后各症状均得到有效缓解。结论 接受安罗替尼治疗的老年肺癌患者的ORR为8.2%,DCR为56.2%，平均PFS为5.2个月，平均OS为11.2个月；年龄≥70岁、三线治疗是其PFS的危险因素。

英文摘要：

【Abstract】　Objective To analyze the efficacy of arotinib in the treatment of elderly patients with lung cancer andprognostic risk factors of patients. Methods A total of 73 elderly patients with lung cancer who were admitted to Huai'an SecondPeople's Hospital from 2018-11-01 to 2020-06-30 were retrospectively selected as the research objects. All patients were treatedwith anlotinib hydrochloride capsules for a total of 21 days. The general data, clinical efficacy [calculation of objective responserate (ORR) and disease control rate (DCR) ] , prognostic indicators [progression-free survival (PFS) , overall survival (OS) ] ,and safety indicators (occurrence of toxic and side effects during the treatment) of patients were collected. Multivariate Logisticregression analysis was used to explore the influencing factors of prognosis (PFS, OS) in elderly patients with lung cancer. ResultsThe ORR of 73 patients was 8.2% (6/73) , and the DCR was 56.2% (41/73) . The ORR and DCR of patients with pathologicalstage Ⅲ were greater than those of patients with pathological stage Ⅳ (P < 0.05) ; the DCR of patients with ECOG score≤ 1 wasgreater than that of patients with ECOG score ≥ 2 (P < 0.05) . The mean PFS of the 73 patients was (5.2±2.0) months, and themean OS was (11.2±3.6) months. Multivariate Logistic regression analysis showed that age [OR=0.270, 95%CI (0.082, 0.882) ] ,third-line treatment [OR=0.127, 95%CI (0.023, 0.704) ] were influencing factors of PFS in elderly patients with lung cancer (P< 0.05) . Among the 73 patients, fatigue occurred in 27 cases (37.0%) , gastrointestinal reaction in 24 cases (32.9%) , bleedingin 8 cases (11.0%) , new hypertension in 6 cases (8.2%) and proteinuria in 5 cases (6.8%) , which were effectively relievedafter treatment with antihypertensive drugs, acid inhibiting and stomach protecting drugs, gastric motility promoting drugs andtraditional Chinese medicine for supplementing Qi and blood. Conclusion The ORR of elderly lung cancer patients treatedwith anlotinib was 8.2%, DCR was 56.2%, average PFS was 5.2 months, and average OS was 11.2 months; age ≥ 70 years old andthird-line treatment are the risk factors of their PFS.

参考文献：